Abstract: Provided herein, among other things, is a method of treating a cancer patient without the need for a tissue biopsy. In some embodiments, the method may comprise (a) performing or having performed a sequencing assay on cell-free DNA (cfDNA) from a sample of blood from the patient to determine if the cell-free DNA comprises actionable and/or non-actionable sequence variations in one or more target genes, and (b) treating the patient using the following method: i. administering a therapy that is targeted to an actionable sequence variation if the patient is identified as having the actionable sequence variation, and ii. administering a non-targeted therapy in the absence of any follow-up genetic testing on DNA extracted from a tissue biopsy if one or more non-actionable sequence variations and no actionable sequence variations are identified.

Abstract: Provided herein is a method of treating non-small cell lung cancer. In some embodiments, the method may comprise monitoring the amount of ctDNA in a patient that is undergoing treatment by pembrolizumab monotherapy for non-small cell lung cancer, identifying the patient as having increasing ctDNA, and administering an effective amount of pembrolizumab and platinum-based doublet chemotherapy to the identified patient.

Abstract: Provided herein, among other things, is a method of treating a cancer patient without the need for a tissue biopsy. In some embodiments, the method may comprise (a) performing or having performed a sequencing assay on cell-free DNA (cfDNA) from a sample of blood from the patient to determine if the cell-free DNA comprises actionable and/or non-actionable sequence variations in one or more target genes, and (b) treating the patient using the following method: i. administering a therapy that is targeted to an actionable sequence variation if the patient is identified as having the actionable sequence variation, and ii. administering a non-targeted therapy in the absence of any follow-up genetic testing on DNA extracted from a tissue biopsy if one or more non-actionable sequence variations and no actionable sequence variations are identified.

Abstract: A pressure sensing system includes a pressure transducer, a pressure manifold, and a heater assembly. The pressure transducer is configured to measure pressures at one or more locations of a vehicle engine. The pressure manifold is configured to cover a face of the pressure transducer and provide an interface for transferring air or gas generated at the one or more locations of the vehicle engine. The heater assembly is configured to heat one or more portions of the pressure transducer and one or more portions of the pressure manifold and maintain a temperature of each of the pressure transducer and the pressure manifold above a predetermined temperature level.

Abstract: Provided herein, among other things, is a method of treating a cancer patient without the need for a tissue biopsy. In some embodiments, the method may comprise (a) performing or having performed a sequencing assay on cell-free DNA (cfDNA) from a sample of blood from the patient to determine if the cell-free DNA comprises actionable and/or non-actionable sequence variations in one or more target genes, and (b) treating the patient using the following method: i. administering a therapy that is targeted to an actionable sequence variation if the patient is identified as having the actionable sequence variation, and ii. administering a non-targeted therapy in the absence of any follow-up genetic testing on DNA extracted from a tissue biopsy if one or more non-actionable sequence variations and no actionable sequence variations are identified.

Abstract: A pressure sensing system includes a pressure transducer, a pressure manifold, and a heater assembly. The pressure transducer is configured to measure pressures at one or more locations of a vehicle engine. The pressure manifold is configured to cover a face of the pressure transducer and provide an interface for transferring air or gas generated at the one or more locations of the vehicle engine. The heater assembly is configured to heat one or more portions of the pressure transducer and one or more portions of the pressure manifold and maintain a temperature of each of the pressure transducer and the pressure manifold above a predetermined temperature level.

Abstract: The use of a 5-HT1B/1D receptor agonist in the treatment or prevention of headache that results from administering an endothelin receptor antagonist; and the combination, comprising an endothelin receptor antagonist and a 5-HT1B/1D receptor agonist is described.

Abstract: A system for generating electrical signals which are intended to control a flow limiting device, in particular in a fuel control apparatus, has duplicate signal generating circuits which are responsive to operation of the fuel control apparatus and which generate nominally indentical output signals when an operating condition of the fuel control apparatus exceeds predetermined limits. Output signals from the duplicate circuits are supplied to the limiting device by way of respective control circuits each of which is enabled by the presence of a corresponding output signal from the other of the signal generating circuits. A device is provided for detecting a malfunction of one of the signal generating circuits and for permanently enabling the control circuit.